Matt O'Brien
Stock Analyst at Piper Sandler
(2.24)
# 2,767
Out of 5,150 analysts
198
Total ratings
43.98%
Success rate
-4.62%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $50 → $28 | $26.26 | +6.63% | 6 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Overweight | $140 → $160 | $148.00 | +8.11% | 14 | Feb 25, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $14 → $21 | $23.74 | -11.54% | 10 | Feb 20, 2026 | |
| GMED Globus Medical | Reiterates: Overweight | $90 → $115 | $91.70 | +25.41% | 13 | Jan 8, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Overweight | $27 → $30 | $23.04 | +30.21% | 2 | Dec 12, 2025 | |
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $0.83 | +49.75% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $13.06 | +37.83% | 2 | Nov 12, 2025 | |
| CNMD CONMED | Maintains: Overweight | $68 → $55 | $43.41 | +26.70% | 14 | Nov 6, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $73.08 | +2.63% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $13.02 | +92.01% | 4 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $26 → $32 | $11.57 | +176.58% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $155 → $82 | $86.75 | -5.48% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $18.67 | +17.84% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $13.21 | +36.26% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $8.18 | +46.70% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $117.75 | +40.13% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $5.26 | -33.46% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $122.19 | +14.58% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $241.84 | +28.18% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $340.16 | -2.99% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $31.46 | +58.93% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $18.92 | -15.43% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $73.85 | +55.72% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $4.81 | +149.48% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $384.59 | +9.21% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $96.71 | -6.94% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $15.34 | +62.97% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.07 | +180.37% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.17 | +41.96% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $97.97 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.36 | +244.04% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $83.37 | +30.44% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $19.03 | +320.39% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.77 | +151.57% | 1 | Jun 24, 2020 |
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Overweight
Price Target: $50 → $28
Current: $26.26
Upside: +6.63%
TransMedics Group
Feb 25, 2026
Maintains: Overweight
Price Target: $140 → $160
Current: $148.00
Upside: +8.11%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $14 → $21
Current: $23.74
Upside: -11.54%
Globus Medical
Jan 8, 2026
Reiterates: Overweight
Price Target: $90 → $115
Current: $91.70
Upside: +25.41%
Kestra Medical Technologies
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $30
Current: $23.04
Upside: +30.21%
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $0.83
Upside: +49.75%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $13.06
Upside: +37.83%
CONMED
Nov 6, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $43.41
Upside: +26.70%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $73.08
Upside: +2.63%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $13.02
Upside: +92.01%
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $11.57
Upside: +176.58%
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $86.75
Upside: -5.48%
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $18.67
Upside: +17.84%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $13.21
Upside: +36.26%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $8.18
Upside: +46.70%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $117.75
Upside: +40.13%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $5.26
Upside: -33.46%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $122.19
Upside: +14.58%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $241.84
Upside: +28.18%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $340.16
Upside: -2.99%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $31.46
Upside: +58.93%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $18.92
Upside: -15.43%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $73.85
Upside: +55.72%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $4.81
Upside: +149.48%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $384.59
Upside: +9.21%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $96.71
Upside: -6.94%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $15.34
Upside: +62.97%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.07
Upside: +180.37%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.17
Upside: +41.96%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $97.97
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.36
Upside: +244.04%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $83.37
Upside: +30.44%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $19.03
Upside: +320.39%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.77
Upside: +151.57%